Greenwich LifeSciences, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for GLSI, updated each market day.
GLSI AI Sentiment
AI sees no strong directional signal for Greenwich LifeSciences, Inc. stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
Sector
Exchange
Market Cap
$357,724,196
Cap Tier
Employees
8
Headquarters
STAFFORD, TX
Listed Since
Sept. 25, 2020
GLSI Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
GLSI Volatility
Greenwich LifeSciences, Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
